`
`lhcrchy ccnify that this correspondence. including listed enclosures is
`being clcctmnically transmitted in Portable Document Fonn (PDF) thmugh
`lEFS—Wcb via Hype-r'l‘cxl 'l'mnsfcr Protocol to the United Slates Patent and
`Tmdcrnnrk OITice's Patent Electmnic Business Center on:
`
`Dated:
`sigmd;
`
`K
`G /1!
`€‘ glib/7-I/I364 ' /%
`
`'
`-
`I
`,
`.
`Attorney Docket No‘ ' 064307
`
`-
`
`-
`
`I 4
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re application of:
`
`Confirmation No.2 4964
`
`Stephen J. BAKER, et al.
`
`Examiner: SHIAO, Rei Tsang
`
`Appl.icationNo.:
`
`ll/357,687
`
`ArtUnit:
`
`I626
`
`Filed: February 16, 2006
`
`For: BORON-CONTA IN ING SMALL
`MOLECULES
`
`RESPONSE TO RESTRICTION
`R EQU IR EM ENT
`
`Customer No.2 43850
`
`
`
`Commissioner for Patents
`PO. Box 1450
`
`Alexandria, VA 223l3-l450
`
`Sir:
`
`In response to the Restriction Requirement dated .March 6, 2008, please enter the
`
`following amendments and remarks.
`
`Amendments to the Claims are reflected in the listing, of claims which begins on page 2 of this
`paper.
`
`Remarks/Arguments begin on page 7 of this paper.
`
`Page I of 7
`
`CFAD Exhibit 1011
`
`CFAD Exhibit 1011
`
`
`
`Appl. No. 11/357,687
`Amdt. dated June 6, 2008
`Response to Restriction Requirement dated March 6, 2008
`
`PATENT
`
`Amendments to the Claims:
`
`This listing of claims will replace all prior versions, and listings of claims in the application.
`
`Listing of Claims:
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`(Cancelled).
`
`JO.
`
`(Cancelled).
`
`11.
`
`(Cancelled).
`
`12.
`
`(Cancelled).
`
`13.
`
`(Cancelled).
`
`14.
`
`(Cancelled).
`
`15.
`
`(Cancelled).
`
`16.
`
`(Cancelled).
`
`Page 2of7
`
`
`
`Appl. No. 11/357,687
`Arndt. dated June 6, 2008
`Response to Restriction Requirement dated March 6, 2008
`
`PATENT
`
`17.
`
`(Cancelled).
`
`18.
`
`(Cancelled).
`
`19.
`
`(Cancelled).
`
`20.
`
`(Cancelled).
`
`21.
`
`(Cancelled).
`
`22.
`
`(Cancelled).
`
`23.
`
`(Cancelled).
`
`24.
`
`(Cancelled).
`
`25.
`
`(Cancelled).
`
`26.
`
`(Cancelled).
`
`27.
`
`(Currently amended) A method of treating or preventing an infection in
`
`2
`
`3
`
`4
`
`an animal, said method comprising administering to the animal a therapeutically effective
`
`amount of 1.3-dihvdro-5-fluoro-1-hydroxv-2.1-benzoxaborole. or a pharmaceuticallv acceptable
`salt thereof or a prodrug thereof. th&-eompouHe aeeording to claim l.
`
`28.
`
`(Original) The method of claim 27, wherein said infection is a member
`
`2
`
`selected from a systemic infection, a cutaneous infection, and an ungual or periungual infection.
`
`29.
`
`(Original) The method of claim 27, wherein said infection is a member
`
`selected from chloronychia, paronychias, erysipcloid, onychorrhexis, gonorrhea, swimming-pool
`
`granuloma, larva migrans, leprosy, Orf nodule, milkers' nodules, herpetic whitlow, acute
`
`bacterial perionyxis, chronic perionyxis, sporotrichosis, syphilis, tuberculosis verrucosa cutis,
`
`tularemia, tungiasis, peri- and subungual warts, zona, nail dystrophy (trachyonychia),
`
`dermatological diseases, psoriasis, pustular psoriasis, alopecia aerata, parakeratosis pustulosa,
`
`contact dermatosis, Reiter's syndrome, psoriasifonn acral dermatitis, lichen planus, idiopathy
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`Page 3of7
`
`
`
`Appl. No. 11/357,687
`Amdt. dated June 6. 2008
`Response to Rcstri~tion Requirement dated March 6, 2008
`
`PATENT
`
`8
`
`9
`
`atrophy in the nails, lichin nitidus, lichen striatus, inflammatory linear verrucous epidermal
`
`naevus (ILVEN), alopecia, pemphigus, bullous pemphigoid, acquired epiderrnolysis bullosa,
`
`l 0 Darier's disease, pityriasis rubra pilaris; palmoplantar keratoderrna, contact eczema, polymorphic
`
`11
`
`12
`
`13
`
`14
`
`15
`
`crythema, scabies, Bazex syndrome, systemic scleroderma, systemic lupus erythcmatosus,
`
`chronic lupus erythematosus, dermatomyositus, Sporotrichosis, Mycotic keratitis, Extension
`
`oculornycosis, Endogenous oculomycosis, Lobomycosis, Mycctoma, Piedra, Pityriasis
`
`vcrsicolor, Tinea corporis, Tinea cruris, Tinea pedis, Tinea barbae, Tinea capitis, Tinea nigra,
`
`Otomycosis, Tinea favosa, Chromomycosis, and Tinea lmbricata.
`
`30.
`
`(Original) The method of claim 27, wherein said infection is
`
`2
`
`onychomycosis.
`
`31.
`
`(Original) The method of claim 27, wherein said animal is a member
`
`selected from a human, cattle, goat, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit,
`
`cat, chicken and turkey.
`
`2
`
`3
`
`32.
`
`(Cancelled).
`
`33.
`
`(Cancelled).
`
`34.
`
`(Cancelled).
`
`35.
`
`(Cancelled).
`
`36.
`
`(Cancelled).
`
`37.
`
`(Cancelled).
`
`38.
`
`(Cancelled).
`
`39.
`
`(Cancelled).
`
`40.
`
`(New) The method of claim 30, wherein said onychomycosis is Tinea
`
`2
`
`unguium.
`
`Page 4of7
`
`
`
`Appl. No. 11/357,687
`Amdt. dated June 6, 2008
`Response to Restriction Requirement dated March 6, 2008
`
`PATENT
`
`41.
`
`(New) The method of claim 27, wherein said method is a method of
`
`2
`
`treating an infection in an animal.
`
`42.
`
`(New) The method of claim 27, wherein said animal is a human.
`
`Page 5of7
`
`
`
`Appl. No. 11/357,687
`Arndt. dated June 6, 2008
`Response to Restriction Requirement dated March 6, 2008
`
`PATENT
`
`REMARKS/ARGUMENTS
`
`I. Status o(tlte Claims
`
`Claims 1-39 are filed in the original application. Claims 1-39 are subject to a
`
`Restriction Requirement. After entry of this Response, claims 27-31 and 40-42 are pending.
`
`Claims 40-42 are nev.'. Claims 27-31 and 40-42 are elected for prosecution on the merits. Claim
`
`27 is amended. No new matter has been added.
`
`Claims l-26 and 32-39 are cancelled without prejudice. Applicants reserve the
`
`right to pursue these claims in another application, such as a continuation or a divisional.
`
`II. Support for tlte amended claims and new claims
`
`Support for amended claim 27 is provided in paragraphs 15-18, 32, I 08 and 25 7.
`
`Support for new claim 40 is provided in paragraph 110. Support for new claim 41 is provided in
`
`paragraph 15. Support for new claim 42 is provided in paragraph 108. No new matter has been
`
`added.
`
`II. Response to the Restriction Requirement
`
`The Examiner has restricted the pending claims into the following seven groups:
`
`Group#
`
`Claim Numbers
`
`I.
`
`IL
`
`III.
`
`JV.
`
`V.
`
`VI.
`
`VII.
`
`portions of 1-2 and 4-18
`
`portions of 1, 3 and 4-18
`
`portions of 1-18
`
`19-26
`
`27-36 (and new claims 40-42)
`
`37-38
`
`39
`
`The claims are restricted into seven groups. Applicants elect Group V for
`
`prosecution on the merits. Each of claims 27-31 and 40-42 fall within Group V.
`
`Page 6 of7
`
`
`
`Appl. No. 111357,687
`Arndt. dated June 6, 2008
`Response to Restriction Requirement dated March 6, 2008
`
`PATENT
`
`a.) Election of Species
`Applicants have been asked to elect one compound as a starting point from which
`
`the Examiner wilJ search the prior art. Applicants elect 1,3-dihydro-5-fluoro-1-hydroxy-2, 1-
`
`benzoxaborole.
`
`CONCLUSION
`
`In view of the foregoing, Applicants believe all claims now pending in this
`Application are in condition for allowance. The issuance of a formal Notice of Allowance at an
`
`early date is respectfully requested.
`
`If the Examiner believes a telephone conference would expedite prosecution of
`
`this application, please telephone the undersigned at 415-442-1000.
`
`Respectfully submitted,
`___...
`
`MORGAN. LEWIS & BOCKIUS LLP
`One Market
`Spear Street Tower
`San Francisco, CA 94105
`Tel: 415-442-1000
`Fax: 415-442-1001
`
`l·SF/7711553.1
`
`Page 7of7